TCI Gene

TCI Gene EBITDA per Share

The EBITDA per Share of TCI Gene (6879.TWO) as of Nov 3, 2026 is 0.72 TWD. In the previous year, EBITDA per Share was 2.14 TWD — a change of -66.36% (lower).

EBITDA per Share

0.72TWD

YoY

-66.36%

Last updated:

EBITDA per Share of TCI Gene is 2025 0.72 TWD. EBITDA per Share of TCI Gene was 2024 2.14 TWD. It decreases by -66.36% lower compared to the previous year.

The TCI Gene EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
2.54 TWD
Jan 1, 2020
2.17 TWD
Jan 1, 2021
4.29 TWD
Jan 1, 2022
3.47 TWD
Jan 1, 2023
0.27 TWD
Jan 1, 2024
2.14 TWD
Jan 1, 2025
0.72 TWD
The TCI Gene EBITDA per Share history
YEAREBITDA per ShareYoY
0.72TWD-66.36%
2.14TWD+688.41%
0.27TWD-92.17%
3.47TWD-19.14%
4.29TWD+97.84%
2.17TWD-14.71%
2.54TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TCI Gene Stock analysis

What does TCI Gene do? TCI GENE, Inc. generates revenue through genetic testing services, virus testing services, and cell experiment services. The company produces adipose-derived stem cell preparations for degenerative arthritis and knee cartilage defects, as well as natural killer cell preparations for solid cancer treatment. Personalized genetic health food is also a key product. These offerings are primarily sold within Taiwan, targeting consumers interested in disease risk assessment, drug genetic testing, and personalized health solutions. The firm's comprehensive genetic testing covers areas like child growth, youth beauty, weight management, and cardiovascular drug responses, while pharmacogenetic testing addresses depression and insomnia. The company's product portfolio includes specialized services such as youth beauty genetic testing and anti-aging genetic testing, which appeal to wellness-focused segments. Adipose-derived stem cell preparations are marketed for orthopedic applications, and natural killer cell preparations target cancer patients seeking alternative therapies. Personalized genetic health food is positioned for consumers seeking tailored nutritional support based on genetic profiles. All products are distributed exclusively in Taiwan, with no international market presence mentioned. TCI GENE, Inc. serves customers seeking preventive health management through genetic insights. The primary buyers are individuals in Taiwan interested in disease risk prediction, drug response optimization, and personalized wellness. The firm's focus on genetic health food and cell-based treatments targets health-conscious consumers and patients requiring specialized medical solutions. Sales are concentrated within Taiwan, reflecting the company's localized market strategy. TCI Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TCI Gene stock

EBITDA per Share of TCI Gene is 0.72 TWD in 2025.

EBITDA per Share of TCI Gene changed from 2.14 TWD to 0.72 TWD, representing a -66.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share TCI Gene since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — TCI Gene

All Key Metrics — TCI Gene